California's insulin initiative is an ill-conceived idea, says analyst

According to a Sydbank analyst, the state’s intention to produce insulin also shouldn’t be viewed as potential competition for makers of the drug like Novo Nordisk.
Photo: Jacob Ehrbahn/Politiken
Photo: Jacob Ehrbahn/Politiken
by marketwire, translated by daniel pedersen

Although California is intending to produce insulin for its own population, efforts to meet demand will hardly be a match for the big drugmakers already supplying the state, says Sydbank analyst Søren Løntoft Hansen. In all likelihood, the end product would be both more expensive and based on older research.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading